Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s stock price was down 7.6% during mid-day trading on Monday . The stock traded as low as $9.63 and last traded at $9.60. Approximately 342,987 shares traded hands during trading, a decline of 52% from the average daily volume of 712,642 shares. The stock had previously closed at $10.39.
Analyst Ratings Changes
A number of brokerages have issued reports on REPL. HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. upped their price objective on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $19.43.
View Our Latest Stock Analysis on REPL
Replimune Group Stock Performance
The firm has a market capitalization of $574.53 million, a PE ratio of -2.43 and a beta of 1.26. The firm's 50 day moving average price is $12.39 and its 200-day moving average price is $12.09. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.
Institutional Investors Weigh In On Replimune Group
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC boosted its position in Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares during the period. Graham Capital Management L.P. grew its holdings in shares of Replimune Group by 6.1% during the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock worth $365,000 after purchasing an additional 1,731 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock valued at $456,000 after buying an additional 2,525 shares during the last quarter. Algert Global LLC raised its position in Replimune Group by 7.1% in the 4th quarter. Algert Global LLC now owns 45,820 shares of the company's stock valued at $555,000 after purchasing an additional 3,057 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock worth $198,000 after buying an additional 3,177 shares during the period. Institutional investors and hedge funds own 92.53% of the company's stock.
About Replimune Group
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
See Also
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
